Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
Adam Sharp(Institute of Cancer Research), Stephen R. Plymate(VA Puget Sound Health Care System), Jonathan Welti(Institute of Cancer Research), Takuma Uo(University of Washington), Wei Yuan(Shanghai Public Health Clinical Center), Colm Morrissey(University of Washington), Antje Neeb(Institute of Cancer Research), David Dolling(Institute of Cancer Research), Lawrence D. True(University of Washington Medical Center), Cynthia C.T. Sprenger(University of Washington), Joshua W. Russo(Beth Israel Deaconess Medical Center), Ruth Riisnaes(Institute of Cancer Research), Peter S. Nelson(Fred Hutch Cancer Center), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Jun Luo(Johns Hopkins University), Daniel Nava Rodrigues(Institute of Cancer Research), Ilsa M. Coleman(Fred Hutch Cancer Center), Suzanne Carreira(Institute of Cancer Research), Steven P. Balk(Beth Israel Deaconess Medical Center), Cláudia Bertan(Institute of Cancer Research), Ines Figueiredo(Institute of Cancer Research), George Seed(Institute of Cancer Research)
Cited by 393
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
|New England Journal of Medicine|2016|1.6k